H.C. Wainwright raised the firm’s price target on Genmab (GMAB) to $36 from $35 and keeps a Buy rating on the shares following the Q2 report. The firm sees potential FDA approval by November 30 for the combination of epcoritamab plus rituximab and lenalidomide for the treatment of adult patients with relapsed or refractory follicular lymphoma.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMAB:
- Genmab’s Tisotumab Vedotin Study: A Promising Update for Solid Tumor Treatment
- Genmab’s Cervical Cancer Study: A Potential Game-Changer?
- Genmab Updates Articles to Boost Financial Flexibility
- Genmab’s Earnings Call Highlights Strong Growth and Pipeline Success
- Genmab Announces Capital Increase Following Employee Warrant Exercise